Glycemic Control and Variability for Congestive Heart Failure Exacerbation

Kathleen Dungan

Status and phase

Completed

Phase 2

Phase 1

Conditions

Diabetes Mellitus

Congestive Heart Failure

Treatments

Drug: Subcutaneous insulin

Drug: Intravenous insulin

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT00812487

1R21DK081877-01 (U.S. NIH Grant/Contract)

2008H0087

Details and patient eligibility

About

High glucose as well as fluctuations (rapid swings) in blood glucose can contribute to severe hospital complications and even death.

Full description

High glucose as well as fluctuations in blood glucose can contribute to severe hospital complications and even death. Studies also suggest that heart failure patients who have high glucose or diabetes do not live as long as patients with normal glucose. Glucose fluctuations have not been well-studied in patients with heart failure. In this study, we will determine whether better control of blood sugar fluctuations in the hospital improve outcomes. We will enroll 80 patients with severe heart failure and divide them into 2 groups. We will use intravenous (given through the vein) insulin to lower blood sugar levels in group 1, and insulin injections (under the skin) in group 2. We will determine whether intravenous insulin improves blood markers of inflammation, changes in vital signs, and other tests that predict mortality in patients with heart failure.

Enrollment

75 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 18 and above
Admitted (less than 48 hours) to the with worsening heart failure
Hyperglycemia or diabetes. Hyperglycemia is defined as blood glucose greater than 150 mg/dL on at least 2 occasions separated by at least 4 hours apart, insulin use, or HbA1c >6.5%.

Exclusion criteria